Cibc World Markets Corp Buys Shares of 6,444 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cibc World Markets Corp purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 6,444 shares of the medical equipment provider's stock, valued at approximately $576,000.

A number of other institutional investors have also recently bought and sold shares of the business. First National Advisers LLC boosted its stake in shares of Lantheus by 4.1% during the 4th quarter. First National Advisers LLC now owns 27,914 shares of the medical equipment provider's stock worth $2,497,000 after acquiring an additional 1,098 shares during the period. Royce & Associates LP bought a new position in Lantheus during the fourth quarter worth $3,330,000. Monimus Capital Management LP acquired a new position in shares of Lantheus in the fourth quarter valued at $653,000. Aurora Investment Counsel increased its holdings in shares of Lantheus by 0.8% in the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock valued at $1,718,000 after purchasing an additional 146 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its position in shares of Lantheus by 39.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 10,814 shares of the medical equipment provider's stock valued at $967,000 after purchasing an additional 3,045 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on LNTH shares. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. Truist Financial increased their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, B. Riley reduced their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Remove Ads

Insider Buying and Selling

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,109 shares of company stock worth $6,110,806. Corporate insiders own 1.50% of the company's stock.

Lantheus Price Performance

NASDAQ:LNTH traded down $1.34 during trading hours on Wednesday, reaching $98.43. 525,962 shares of the company were exchanged, compared to its average volume of 932,124. The company has a market capitalization of $6.74 billion, a P/E ratio of 16.38 and a beta of 0.38. The business has a 50 day moving average of $92.91 and a 200 day moving average of $96.45. Lantheus Holdings, Inc. has a 1-year low of $57.92 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.